BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Dec 19, 2014
Insider Transaction Report
Form 4
McGuyer Frank B.
Director
Transactions
- Exercise of In-Money
Series C Convertible Preferred Stock
2014-12-17+333,536→ 196,197 total(indirect: By McGuyer Investments Ltd.)→ Common Stock (196,197 underlying) - Exercise of In-Money
Warrant to Purchase Series C Preferred Stock (right to buy)
2014-12-17−333,536→ 0 total(indirect: By McGuyer Investments Ltd.)Exercise: $6.00From: 2014-08-22Exp: 2019-08-22→ Series C Preferred Stock (333,536 underlying)
Footnotes (3)
- [F1]The Reporting Person has voting and investment power over the securities held by McGuyer Investments Ltd. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F2]Upon the date immediately following the date of the effectiveness of the initial public offering of the Issuer, on or prior to March 31, 2015, the warrants will be terminated if not previously exercised.
- [F3]The Series C Convertible Preferred Stock (the "Preferred Stock") are convertible into the Issuer's common stock at a conversion rate of 1 share of common stock for each 1.7 shares of Preferred Stock and have no expiration date.